Patient travel challenges in the rra of PPRT

#3111

Introduction: PRRT has been used for the treatment of advanced somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. Most commonly used forms of PRRT are Lutetium 177 labelled DOTATATE (Lutathera, Advanced Accelerator Applications, a Novartis company) which was recently approved by U.S. Food and Drug Administration (FDA) and Yttrium 90 labelled DOTATATE. In our experience, it is not uncommon for patients recently treated with PRRT to be stopped by United States Customs and Border Protection (CBP) officers while traveling, due to the detection of residual radiation activity.

Aim(s): Present results of an online public survey about patient experience with travel after PRRT.

Materials and methods: An online public survey performed by one of our authors (JAM) regarding patient experience at the US ports of entry and high security areas after PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kendi A

Authors: Kendi A, Halfdanarson T, Naraev B, Mercer D, Underwood J,

Keywords: theranostics, PRRT, lutetium-177-dotatate,